Glioblastoma in natalizumab-treated multiple sclerosis patients

Fabian Sierra Morales, Robert B. Wright, Jorge Novo, Leonidas D. Arvanitis, Dusan Stefoski, Igor J. Koralnik*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


We present two natalizumab-treated multiple sclerosis patients who developed glioblastoma multiforme (GBM) with variable outcomes. One patient had an isocitrate dehydrogenase (IDH)-wildtype GBM with aggressive behavior, who declined treatment and died 13 weeks after symptoms onset. The other patient underwent resection of an IDH-mutant secondary GBM that arose from a previously diagnosed grade II astrocytoma. He is still alive 5 years after the diagnosis of GBM. JC virus was not detected in either case. Whether natalizumab played a role in the development of GBM in those patients deserves further investigation.

Original languageEnglish (US)
Pages (from-to)512-516
Number of pages5
JournalAnnals of clinical and translational neurology
Issue number7
StatePublished - Jul 1 2017

ASJC Scopus subject areas

  • General Neuroscience
  • Clinical Neurology


Dive into the research topics of 'Glioblastoma in natalizumab-treated multiple sclerosis patients'. Together they form a unique fingerprint.

Cite this